US Pharma MarketingNovocure’s electric fields therapy fails key glioblastoma study
Novocure Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug pricing and the IRA: Tracking the government's negotiation power FDA policy and drug approvals: What’s changing…
Novocure reported Thursday morning that its electric fields device combined with chemoradiation failed to extend glioblastoma patients' lives in a Phase 3 study, dampening the company's hopes of expanding its product's ...
Source: Endpoints News